TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma
- 25 October 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Scandinavian Journal of Gastroenterology
- Vol. 55 (12), 1433-1440
- https://doi.org/10.1080/00365521.2020.1837928
Abstract
Plasma circulating tumor DNA (ctDNA) with tumor-specific mutations is an attractive biomarker. The telomerase reverse transcriptase (TERT) C228T promoter mutation is the most prevalent tumor-associated mutation in hepatocellular carcinoma (HCC). We evaluated the presence and prognostic value of the TERT C228T mutation in plasma and tissue in a Danish HCC cohort. We analyzed ctDNA from 95 HCC patients and 45 liver cirrhotic patients without HCC for the TERT mutation using droplet digital polymerase chain reaction. We also analyzed DNA from the corresponding primary tumor tissues in 34 HCC patients. The plasma TERT C228T mutation was detected in 42/95 HCC patients (44%) but in none of the non-HCC patients. The TERT mutation was detected in 23/34 tumor samples (68%). The TERT mutation was associated with increased mortality when detected in plasma (adjusted HR 2.16 (1.20–3.88), p = .010) but not in tumor tissue (adjusted HR 1.11 (0.35–3.56), p = .860). There was a positive correlation between the presence of the TERT mutation in plasma and an advanced TNM stage (p < .0001) and vascular invasion (p = .005). Analysis of the TERT mutation in plasma and tumor DNA from the same patient was concordant in 21/34 samples (62%; kappa value 0.31, p = .014). Non-concordance was associated with an early TNM stage. The plasma TERT mutation was detected in 44% of HCC patients and in none of non-HCC cirrhotic patients; and was associated with increased mortality. We propose the TERT C228T mutation in ctDNA as a promising HCC biomarker for prognosis.Keywords
This publication has 29 references indexed in Scilit:
- Determining lower limits of detection of digital PCR assays for cancer-related gene mutationsBiomolecular Detection and Quantification, 2014
- Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosisJournal of Hepatology, 2014
- Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor‐sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinibCancer, 2014
- TERT promoter mutation in resectable hepatocellular carcinomas: A strong association with hepatitis C infection and absence of hepatitis B infectionInternational Journal of Surgery, 2014
- Minocycline, a microglial inhibitor, blocks spinal CCL2-induced heat hyperalgesia and augmentation of glutamatergic transmission in substantia gelatinosa neuronsJournal of Neuroinflammation, 2014
- High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesionsNature Communications, 2013
- EGFR Tyrosine Kinase Inhibitor Pelitinib Regulates Radiation-Induced p65-Dependent Telomerase Activation in Squamous Cell CarcinomaRadiation Research, 2013
- Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cellsCancer Letters, 2012
- Clonal evolution in cancerNature, 2012
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2008